Latest From Alzheon Inc.
Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.
There were only two biopharma IPOs in the US during August, bringing the year's total to 47. But with eight new filings in August, launches in September could rival July's total of nine first-time offerings, especially since this average return on this year's IPOs remains in positive territory.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Alzheon Inc.
- Senior Management
Martin Tolar, MD, PhD, Pres. & CEO
John Hey, PhD, CSO
Kenneth Mace, VP, Fin.
Petr Kocis, PhD, VP, Preclinical Dev.
Susan Abushakra, MD, CMO
- Contact Info
Phone: (857) 214-7242
111 Speen St.
Framingham,, MA 01701
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.